Contact Us

Agilent Technologies Registers Cedar Creek Facility with FDA to Manufacture Diagnostic Products


SANTA CLARA Calif., June 27, 2011

Agilent Technologies Inc. (NYSE: A) today announced that its Cedar Creek, Texas, reagent manufacturing facility has been registered with the U.S. Food and Drug Administration as a medical device establishment. This registration is required for the manufacture of diagnostic products, which Agilent intends to develop.

"Many of Agilent's proven research platforms hold potential in diagnostic markets," said Robert Schueren, Agilent vice president, Genomics. "We've made a commitment to bring improved diagnostic tools to the medical community. Having an FDA-registered manufacturing facility is yet another step in this endeavor."

Agilent currently manufactures and packages a wide range of research bioreagents at the 80,000-square-foot Cedar Creek facility, including enzyme-based reagents and high-fidelity oligonucleotides. The company has built separate, dedicated diagnostics space with additional room for expansion as needed.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company's 18,500 employees serve customers in more than 100 countries. Agilent had net revenues of $5.4 billion in fiscal 2010. Information about Agilent is available at

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding Agilent's future revenues, earnings and profitability and the future demand for the company's products and services. These forward-looking statements involve risks and uncertainties that could cause Agilent's results to differ materially from management's current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers' businesses, unforeseen changes in the demand for current and new products and technologies, and the risk that we are not able to realize the savings expected from integration and restructuring activities.

In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that our cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on our operations, our markets and our ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of our supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; and other risks detailed in Agilent's filings with the Securities and Exchange Commission. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

# # #


Stuart Matlow
+1 408 553 7191